Showing 6461-6470 of 7273 results for "".
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Xeljanz Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121118-xeljanz_approved_for_rheumatoid_arthritis/2459679/The FDA recently approved Xeljanz (tofacitinib) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to, or who are intolerant of, methotrexate. The decision comes ahead of the product's prescription drug user fee goal date of Nov
- Allergan to Acquire SkinMedicahttps://practicaldermatology.com/news/20121116-allergan_to_acquire_skinmedica/2459680/Allergan, Inc. is set to acquire SkinMedica's topical aesthetics skin care business, in a deal estimated at approximately $350 million up-front. Allergan will also pay SkinMedica an additional $25 million contingent upon the acquired products achieving a specific level of net sales. The acquisition
- Dermatology Partnerships Exploredhttps://practicaldermatology.com/news/20121115-dermatology_partnerships_explored/2459681/Research and Markets has added the "Dermatology Partnering Terms and Agreements" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter dermatology
- Belotero Now Available Nationwidehttps://practicaldermatology.com/news/20121106-ha-based_dermal-filler_released_by_merz/2459684/Belotero Balance, a dermal filler for the correction of moderate-to-severe facial wrinkles and folds, is now available nationwide from Merz Aesthetics. This dermal filler joins the Merz Aesthetics portfolio of injectable products, includin
- Cosmetic Surgery Forum Names Honoreeshttps://practicaldermatology.com/news/20121101-cosmetic_surgery_forum_names_honorees/2459685/Richard Fitzpatrick, MD and Diane Ranger, founder of Colorescience, will receive the “Innovators in Dermatology Award” at Cosmetic Surgery Forum 2012 in Las Vegas, November 29 through December 1. Jonah Schacknai, Founder and CEO of Medicis Pharmaceuticals, will receive the Lifetime Service Award. Re
- Asclera's "Stand and Deliver" to Recognize Inspirational Womenhttps://practicaldermatology.com/news/20121101-ascleras_stand_and_deliver_to_recognize_inspirational_women/2459686/Nominations are being accepted through December 31, 2012 for the Stand and Deliver program sponsored by Merz Aesthetics, exclusive distributor of Asclera® (polidocanol) injec
- "Cirque du CeraVe" Event in NYC Launches New CeraVe Productshttps://practicaldermatology.com/news/20121031-cirque_du_cerave_event_in_nyc_launches_new_cerave_products/2459687/The “Cirque du CeraVe” skincare launch event, held at Osteria del Circo in New York City on October, was attended by consumer, trade and dermatology media, who learned about new CeraVe product launches. The brand staged a CeraVe “Circus” complete with a professional mime, juggler, contortionist and
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design